Imperatorin Inhibits Proliferation, Migration, and Inflammation via Blocking the NF-κB and MAPK Pathways in Rheumatoid Fibroblast-like Synoviocytes
Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for natural compounds that may suppress the activation of FLSs has become a complementary approach for RA treatment. Here, we investigated the e...
Saved in:
Published in: | ACS omega Vol. 7; no. 34; pp. 29868 - 29876 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
American Chemical Society
30-08-2022
|
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for natural compounds that may suppress the activation of FLSs has become a complementary approach for RA treatment. Here, we investigated the effects and mechanisms of imperatorin (IPT) on proliferation, migration, and inflammation in primary cultured arthritic FLSs. We found that IPT significantly suppressed TNFα-induced proliferation and migration of arthritic FLSs, but showed little effect on survival and apoptosis. In addition, IPT treatment significantly reduced the TNFα-induced expression of pro-inflammatory cytokines (IL-1β, TNFα, IL-6, and IL-8) in arthritic FLSs. Further mechanism studies suggested that IPT inhibited the activations of p38 and extracellular signal-regulated kinase (ERK). Also, IPT blocked the nuclear factor of κB (NF-κB) activation by suppressing the phosphorylation and degradation of IκBα, thereby preventing the translocation of p65. Collectively, our results demonstrated that IPT could inhibit the over-activated phenotypes of arthritic FLSs via the mitogen-activated protein kinase (MAPK) (p38 and ERK) and NF-κB pathways leading to the down-regulation of pro-inflammatory cytokines, which might be beneficial to the anti-proliferative and anti-migratory activities of FLS cells. These findings suggest that IPT has the potential to be developed as a novel agent for RA treatment. |
---|---|
AbstractList | Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for natural compounds that may suppress the activation of FLSs has become a complementary approach for RA treatment. Here, we investigated the effects and mechanisms of imperatorin (IPT) on proliferation, migration, and inflammation in primary cultured arthritic FLSs. We found that IPT significantly suppressed TNFα-induced proliferation and migration of arthritic FLSs, but showed little effect on survival and apoptosis. In addition, IPT treatment significantly reduced the TNFα-induced expression of pro-inflammatory cytokines (IL-1β, TNFα, IL-6, and IL-8) in arthritic FLSs. Further mechanism studies suggested that IPT inhibited the activations of p38 and extracellular signal-regulated kinase (ERK). Also, IPT blocked the nuclear factor of κB (NF-κB) activation by suppressing the phosphorylation and degradation of IκBα, thereby preventing the translocation of p65. Collectively, our results demonstrated that IPT could inhibit the over-activated phenotypes of arthritic FLSs via the mitogen-activated protein kinase (MAPK) (p38 and ERK) and NF-κB pathways leading to the down-regulation of pro-inflammatory cytokines, which might be beneficial to the anti-proliferative and anti-migratory activities of FLS cells. These findings suggest that IPT has the potential to be developed as a novel agent for RA treatment. Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for natural compounds that may suppress the activation of FLSs has become a complementary approach for RA treatment. Here, we investigated the effects and mechanisms of imperatorin (IPT) on proliferation, migration, and inflammation in primary cultured arthritic FLSs. We found that IPT significantly suppressed TNFα-induced proliferation and migration of arthritic FLSs, but showed little effect on survival and apoptosis. In addition, IPT treatment significantly reduced the TNFα-induced expression of pro-inflammatory cytokines (IL-1β, TNFα, IL-6, and IL-8) in arthritic FLSs. Further mechanism studies suggested that IPT inhibited the activations of p38 and extracellular signal-regulated kinase (ERK). Also, IPT blocked the nuclear factor of κB (NF-κB) activation by suppressing the phosphorylation and degradation of IκBα, thereby preventing the translocation of p65. Collectively, our results demonstrated that IPT could inhibit the over-activated phenotypes of arthritic FLSs via the mitogen-activated protein kinase (MAPK) (p38 and ERK) and NF-κB pathways leading to the down-regulation of pro-inflammatory cytokines, which might be beneficial to the anti-proliferative and anti-migratory activities of FLS cells. These findings suggest that IPT has the potential to be developed as a novel agent for RA treatment. |
Author | Zhou, Junnan Yu, Xiaolu Chen, Gang Mao, Yuhang Wang, Chaoliang Ma, Xuemei Lin, Wei Liu, Mei |
AuthorAffiliation | Spine and Joint Surgery People’s Hospital Affiliated to Shandong First Medical University Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences |
AuthorAffiliation_xml | – name: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences – name: People’s Hospital Affiliated to Shandong First Medical University – name: Spine and Joint Surgery |
Author_xml | – sequence: 1 givenname: Wei surname: Lin fullname: Lin, Wei organization: People’s Hospital Affiliated to Shandong First Medical University – sequence: 2 givenname: Gang surname: Chen fullname: Chen, Gang organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences – sequence: 3 givenname: Yuhang surname: Mao fullname: Mao, Yuhang organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences – sequence: 4 givenname: Xuemei surname: Ma fullname: Ma, Xuemei organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences – sequence: 5 givenname: Junnan surname: Zhou fullname: Zhou, Junnan organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences – sequence: 6 givenname: Xiaolu surname: Yu fullname: Yu, Xiaolu organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences – sequence: 7 givenname: Chaoliang surname: Wang fullname: Wang, Chaoliang email: lwwcl2003@163.com organization: People’s Hospital Affiliated to Shandong First Medical University – sequence: 8 givenname: Mei orcidid: 0000-0002-4960-0096 surname: Liu fullname: Liu, Mei email: meiliunj@163.com organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences |
BookMark | eNp1kc9O3DAQxq0KVCjl3qOPPRCwncRJLpUAddsV0K7652w5znhjcOzFTrba9-jT9CH6TBh2qdpDTx7N_L5vNP5eoT3nHSD0hpJTShg9kyr6AZbylCnCKs5foENWVCSjeZHv_VUfoOMYbwkhlNesZvwlOsg54ZQ39BD9nA8rCHL0wTg8d71pzRjxInhr9GPfeHeCb8zyuZSuS5i2chieOnhtJL6wXt0Zt8RjD_jTLPv96-IJvDlfXOGFHPsfchNxWvClhynpvOnwzLTBt1bGMbPmDvDXjfNr49VmhPga7WtpIxzv3iP0ffb-2-XH7Przh_nl-XUmWVnyDChtdFEVLS-5IpyUALRtOqVbWQGvNWk6ynQ6FDSjDOqiprIkoFhZ6VrVLD9C77a-q6kdoFPgxiCtWAUzyLARXhrx78SZXiz9WjRFXlQVSQZvdwbB308QRzGYqMBa6cBPUbCKNA3NaV4llGxRFXyMAfSfNZSIxzzFc55il2eSnGwlaSJu_RRc-oz_4w9k4KgD |
CitedBy_id | crossref_primary_10_1007_s12018_024_09290_7 crossref_primary_10_1007_s10787_023_01369_9 crossref_primary_10_1016_j_ejphar_2023_176250 crossref_primary_10_3389_fphar_2023_1230293 crossref_primary_10_3390_ijms242115793 |
Cites_doi | 10.1016/j.jbspin.2011.03.018 10.1021/acs.analchem.5b04064 10.3390/biom9120795 10.1186/s12979-019-0169-4 10.1186/s13075-019-1935-6 10.3892/etm.2016.3172 10.1016/j.toxlet.2011.11.030 10.3892/or.2016.4586 10.1093/rheumatology/kem298 10.1007/s10456-015-9477-2 10.1021/jf204297e 10.1038/s41413-018-0016-9 10.1021/acs.analchem.7b03114 10.1016/j.yrtph.2014.05.025 10.1186/ar3324 10.1093/rheumatology/kel065 10.1016/j.snb.2020.128486 10.1016/j.bcp.2020.114401 10.1007/s00044-014-1233-4 10.1073/pnas.1814777116 10.3109/08830185.2014.938325 10.1016/j.intimp.2019.03.008 10.2147/BTT.S35475 10.1101/cshperspect.a001651 10.1080/21655979.2021.2012949 10.1016/j.autrev.2020.102741 10.1111/j.0105-2896.2009.00859.x 10.1002/art.40504 10.1039/c7fo01748k 10.3892/mmr.2017.7706 10.1038/s41413-019-0047-x 10.1007/s10753-020-01371-1 10.1006/cimm.1994.1223 10.3390/ijms19051514 10.1016/j.intimp.2021.107392 10.1038/nprot.2007.173 10.1002/jcp.26754 10.1186/ar1038 10.1038/nbt1328 10.1186/s12967-021-03169-7 10.1016/j.cmet.2010.12.008 10.1186/1471-2474-12-153 10.3389/fphar.2021.670707 10.4049/jimmunol.1600600 10.1038/s41423-019-0201-9 10.1155/2020/2138186 10.1002/pds.3221 10.1155/2021/6617312 10.1016/j.toxicon.2019.06.007 10.3390/ijms23105813 |
ContentType | Journal Article |
Copyright | 2022 The Authors. Published by American Chemical Society 2022 The Authors. Published by American Chemical Society 2022 The Authors |
Copyright_xml | – notice: 2022 The Authors. Published by American Chemical Society – notice: 2022 The Authors. Published by American Chemical Society 2022 The Authors |
DBID | N~. AAYXX CITATION 7X8 5PM |
DOI | 10.1021/acsomega.2c02766 |
DatabaseName | American Chemical Society Journals CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 2470-1343 |
EndPage | 29876 |
ExternalDocumentID | 10_1021_acsomega_2c02766 c301267890 |
GrantInformation_xml | – fundername: ; grantid: NA |
GroupedDBID | 53G ABFRP ABUCX ACS ADBBV AFEFF ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV EBS GROUPED_DOAJ HYE N~. OK1 RPM VF5 AAFWJ AAHBH AAYXX AFPKN CITATION M~E 7X8 5PM |
ID | FETCH-LOGICAL-a2556-e119f474b656c0605ee1b9dcfba7e68f09d12f616ef212e8481a50ec257f8c823 |
IEDL.DBID | RPM |
ISSN | 2470-1343 |
IngestDate | Tue Sep 17 21:34:14 EDT 2024 Fri Aug 16 23:51:50 EDT 2024 Fri Aug 23 01:21:48 EDT 2024 Thu Sep 01 03:10:33 EDT 2022 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 34 |
Language | English |
License | Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a2556-e119f474b656c0605ee1b9dcfba7e68f09d12f616ef212e8481a50ec257f8c823 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4960-0096 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434770/ |
PMID | 36061691 |
PQID | 2709913137 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9434770 proquest_miscellaneous_2709913137 crossref_primary_10_1021_acsomega_2c02766 acs_journals_10_1021_acsomega_2c02766 |
PublicationCentury | 2000 |
PublicationDate | 20220830 |
PublicationDateYYYYMMDD | 2022-08-30 |
PublicationDate_xml | – month: 08 year: 2022 text: 20220830 day: 30 |
PublicationDecade | 2020 |
PublicationTitle | ACS omega |
PublicationTitleAlternate | ACS Omega |
PublicationYear | 2022 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref9/cit9 ref45/cit45 ref3/cit3 ref27/cit27 ref52/cit52 ref23/cit23 ref8/cit8 ref31/cit31 ref2/cit2 ref34/cit34 ref37/cit37 ref20/cit20 ref48/cit48 ref17/cit17 ref10/cit10 ref35/cit35 ref53/cit53 ref21/cit21 ref42/cit42 ref46/cit46 ref49/cit49 ref13/cit13 ref24/cit24 ref38/cit38 Zhai K. (ref19/cit19) 2014; 76 ref50/cit50 ref6/cit6 ref36/cit36 ref18/cit18 ref11/cit11 ref25/cit25 ref29/cit29 ref32/cit32 ref39/cit39 ref14/cit14 ref5/cit5 ref51/cit51 ref43/cit43 ref28/cit28 ref40/cit40 Li-xin W. (ref16/cit16) 2018 ref26/cit26 ref12/cit12 ref15/cit15 ref41/cit41 ref22/cit22 ref33/cit33 ref4/cit4 ref30/cit30 ref47/cit47 ref1/cit1 ref44/cit44 ref7/cit7 |
References_xml | – ident: ref44/cit44 doi: 10.1016/j.jbspin.2011.03.018 – ident: ref11/cit11 doi: 10.1021/acs.analchem.5b04064 – ident: ref5/cit5 doi: 10.3390/biom9120795 – ident: ref30/cit30 doi: 10.1186/s12979-019-0169-4 – volume: 76 start-page: 445 year: 2014 ident: ref19/cit19 publication-title: Indian J. Pharm. Sci. contributor: fullname: Zhai K. – ident: ref4/cit4 doi: 10.1186/s13075-019-1935-6 – ident: ref18/cit18 doi: 10.3892/etm.2016.3172 – ident: ref50/cit50 doi: 10.1016/j.toxlet.2011.11.030 – ident: ref15/cit15 doi: 10.3892/or.2016.4586 – ident: ref47/cit47 doi: 10.1093/rheumatology/kem298 – ident: ref31/cit31 doi: 10.1007/s10456-015-9477-2 – ident: ref17/cit17 doi: 10.1021/jf204297e – ident: ref39/cit39 doi: 10.1038/s41413-018-0016-9 – ident: ref10/cit10 doi: 10.1021/acs.analchem.7b03114 – ident: ref51/cit51 doi: 10.1016/j.yrtph.2014.05.025 – ident: ref27/cit27 doi: 10.1186/ar3324 – ident: ref28/cit28 doi: 10.1093/rheumatology/kel065 – ident: ref12/cit12 doi: 10.1016/j.snb.2020.128486 – ident: ref35/cit35 doi: 10.1016/j.bcp.2020.114401 – ident: ref36/cit36 doi: 10.1021/jf204297e – start-page: 20 year: 2018 ident: ref16/cit16 publication-title: Chin. J. Exp. Tradit. Med. Formulae contributor: fullname: Li-xin W. – ident: ref52/cit52 doi: 10.1007/s00044-014-1233-4 – ident: ref13/cit13 doi: 10.1073/pnas.1814777116 – ident: ref25/cit25 doi: 10.3109/08830185.2014.938325 – ident: ref32/cit32 doi: 10.1016/j.intimp.2019.03.008 – ident: ref14/cit14 doi: 10.2147/BTT.S35475 – ident: ref45/cit45 doi: 10.1101/cshperspect.a001651 – ident: ref40/cit40 doi: 10.1080/21655979.2021.2012949 – ident: ref26/cit26 doi: 10.1016/j.autrev.2020.102741 – ident: ref3/cit3 doi: 10.1111/j.0105-2896.2009.00859.x – ident: ref6/cit6 doi: 10.1002/art.40504 – ident: ref20/cit20 doi: 10.1039/c7fo01748k – ident: ref37/cit37 doi: 10.3892/mmr.2017.7706 – ident: ref38/cit38 doi: 10.1038/s41413-019-0047-x – ident: ref9/cit9 doi: 10.1007/s10753-020-01371-1 – ident: ref8/cit8 doi: 10.1006/cimm.1994.1223 – ident: ref34/cit34 doi: 10.3390/ijms19051514 – ident: ref2/cit2 doi: 10.1016/j.intimp.2021.107392 – ident: ref7/cit7 doi: 10.1038/nprot.2007.173 – ident: ref33/cit33 doi: 10.1002/jcp.26754 – ident: ref21/cit21 doi: 10.1186/ar1038 – ident: ref48/cit48 doi: 10.1038/nbt1328 – ident: ref23/cit23 doi: 10.1186/s12967-021-03169-7 – ident: ref46/cit46 doi: 10.1016/j.cmet.2010.12.008 – ident: ref24/cit24 doi: 10.1186/1471-2474-12-153 – ident: ref53/cit53 doi: 10.3389/fphar.2021.670707 – ident: ref29/cit29 doi: 10.4049/jimmunol.1600600 – ident: ref22/cit22 doi: 10.1038/s41423-019-0201-9 – ident: ref41/cit41 doi: 10.1155/2020/2138186 – ident: ref1/cit1 doi: 10.1002/pds.3221 – ident: ref42/cit42 doi: 10.1155/2021/6617312 – ident: ref49/cit49 doi: 10.1016/j.toxicon.2019.06.007 – ident: ref43/cit43 doi: 10.3390/ijms23105813 |
SSID | ssj0001682826 |
Score | 2.2455704 |
Snippet | Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for... Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for... |
SourceID | pubmedcentral proquest crossref acs |
SourceType | Open Access Repository Aggregation Database Publisher |
StartPage | 29868 |
SummonAdditionalLinks | – databaseName: American Chemical Society Journals dbid: ACS link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NjtMwELbY5QAX_hHlT0aCAxIG20lj57hbtmKFdlVRkLhFtjPeWoCDSLuo78HT8BA8E-M0YbcIIbhFysSxZiaZbzz2N4Q8HvOae28cg3RsOedgGabNOXPKltJq0BK6JrZzdfxevzw4T5PzewVfihfGtc0nODHPpcMUqih2yEWpECgkGDSZn62nFJg7dN3VZK44E1me9VXJPw2SYpFrt2PRGcDc3h55Lt5Mr_7PTK-RKz2qpHsbN7hOLkC8QS5NhmZuN8m3Q4THXUU9RHoYF8GGZUtnqWWPh40TPKNH4WS4NLFGMY_usjnaSE-DofsY-NLKOkXQSI-n7Mf3_U7waG_2ms4QSn4165biC94sYIXPNaGmU0zHG4sQfck-hg9A5-vYnIbGrRHi3iLvpgdvJ69Y35CBmcRUxkCI0ucqtwgCHcdECEDYsnbeGgWF9ryshfSFKMBjRITE1G_GHBz-Frx2Wma3yW5sItwh1GAi53PQtXZZbn1hODrL2OY-q4UuQYzIE1Rn1X9QbdXVyqWoBh1XvY5H5Olgwurzhp_jL7KPBhtXqP5UGTERmlVboUMhTs5EpkZEbRn_16CJhnv7TgyLjo47Mewpxe_-44zvkcsyHaFI69L8PtldflnBA7LT1quHnUf_BEen93Q priority: 102 providerName: American Chemical Society |
Title | Imperatorin Inhibits Proliferation, Migration, and Inflammation via Blocking the NF-κB and MAPK Pathways in Rheumatoid Fibroblast-like Synoviocytes |
URI | http://dx.doi.org/10.1021/acsomega.2c02766 https://search.proquest.com/docview/2709913137 https://pubmed.ncbi.nlm.nih.gov/PMC9434770 |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELboXuCC-BXlpzISHJBI6zhp7Rx3y1asUFcVBYlbZDvjrcXWWZF2Ud-Dp-EheCbGbgLbCwdukWInkWei-ebvG0JejVnFrFUmgdC2nDPQCbrNeWKELriWIDnEIbZLcf5FvjsNNDnjrhcmFu0b7Yb-cj30bhVrK6_WZtTViY0W82ngNBOCjXqkh9jwhoseAysTdCJ4l5JEEzZSpqnXcKGG3KATNglTizLE7YEmJtgk0xzapL9A87BM8obdmd0jd1vASI_3H3af3AL_gNyednPaHpIfZ4h8Y7LceXrmV067TUMXYRqPhb1839K5u-gula9wmUVN2Hct0mun6AnatBA0p4gH6fks-fXzJC6cHy8-0AWixO9q11B8wccVbHFf7So6Q0-71oi-N8ml-wp0ufP1tavNDtHrI_J5dvpp-j5pZy0kKpCQJZCmhc1FrhHfGYY-DkCqi8pYrQRMpGVFlXKLZwYWjR0EEn41ZmDwj7fSSJ49Jke-9vCEUIU-ms1BVtJkubYTxVAPxjq3WZXKAtI-eY1nXrb_SlPGNDhPy05MZSumPnnTSaW82lNv_GPty05sJR5_SHooD_W2KblADJxmaSb6RBzI889DA8P24R1UvMi03Sra0__e-Yzc4aFfIgSh2XNytPm2hRek11TbAaL46XIQYwCDqMG_AakR-g4 |
link.rule.ids | 230,315,729,782,786,866,887,2769,27085,27933,27934,53800,53802,56747,56797 |
linkProvider | National Library of Medicine |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtswDBbW7tBd9j80-9WA7TBgTiTZieVjmzVo0CYI1g7YzZBkqhHWyMWcdMh77Gn2EHumUY69NZcdejNgyTZEyvwokh8JeddnBbNWmQhC2XLCQEfoNieRSXUmtAQpoG5ie5ZOv8pPR4Emp9_WwtRJ-0a7rr9cdL2b17mVVwvTa_PEerPJMHCapSnr7ZC7uF8Zu-Gk10crA3QjRBuURCPWU6YqF3ChusKgGzYIfYtiRO6BKCZYJVNtW6V_UHM7UfKG5Rk9uOU3PyT3G6hJDza3H5E74B-TvWHb4e0J-TlGzFyH2Z2nYz932i0rOgt9fCxsNOMjnbiL9lL5AodZ1KFNvSO9dooeojUMx-0UkSSdjqLfvw7rgZOD2QmdIb78odYVxRd8nsMK55WuoCP00UuNuH0ZXbpvQM_Wvrx2pVkj7n1KvoyOzofHUdOlIVKBviwCzjObpIlGZGgYekcAXGeFsVqlMJCWZQUXFtcaLJpJCPT9qs_A4L_CSiNF_Izs-tLDPqEKvTubgCykiRNtB4qhBvV1YuOCywx4h7xHWeXNLqvyOoAueN6KN2_E2yEfWmnmVxvSjv-MfduKO8flD-ES5aFcVblIET3zmMdph6RbevD3oYGbe_sOir_m6G7E_fzWM9-QvePzyWl-Op6evCD3RKi6CEfZ7CXZXX5fwSuyUxWr17Xm_wGXJA26 |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwELfYkICX8V-U8cdI8IBEGsdJm-Rx6xZRjVYRA4m3yHbOq8XqVKTd1O-xT8OH4DNxTpOxvvAAb5FyTiLfOfc73_l3hLwdsJJpLZQH7thyxEB6GDZHnoplymUCCYemie1pPP2WHB07mpzrVl9N0b6Spm_P531rZk1t5WKu_K5OzM8nI8dpFsfMX5Ta3yG3cc0yfiNQb7ZXhhhK8C4xiY7MF6qu5nAm-lxhKDZ0vYtCRO-OLMZ5JlVve6Y_cHO7WPKG98nu_8d3PyB7LeSkBxuRh-QW2Efk7qjr9PaYXI0ROzfpdmPp2M6MNMua5q6fj4aNhXygE3PWXQpbophGW9qce6QXRtBD9Ipu250ioqTTzPv187ARnBzkJzRHnHkp1jXFF3yewQrHVaakGcbqlUT8vvTOzXegp2tbXZhKrRH_PiFfs-Mvo49e263BE47GzIMgSHUURxIRomIYJQEEMi2VliKGYaJZWgZc43yDRncJjsZfDBgo_GfoRCU8fEp2bWXhGaECozwdQVImKoykHgqGljSQkQ7LIEkh6JF3qK-iXW110STSeVB0Ki5aFffI-06jxWJD3vEX2Tedygucfpc2ERaqVV3wGFF0EAZh3CPxli1cP9RxdG_fQRNouLpblT__55GvyZ38KCs-jacn--Qed4cv3I42e0F2lz9W8JLs1OXqVWP8vwHsuxA6 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Imperatorin+Inhibits+Proliferation%2C+Migration%2C+and+Inflammation+via+Blocking+the+NF-%CE%BAB+and+MAPK+Pathways+in+Rheumatoid+Fibroblast-like+Synoviocytes&rft.jtitle=ACS+omega&rft.au=Lin%2C+Wei&rft.au=Chen%2C+Gang&rft.au=Mao%2C+Yuhang&rft.au=Ma%2C+Xuemei&rft.date=2022-08-30&rft.eissn=2470-1343&rft.volume=7&rft.issue=34&rft.spage=29868&rft.epage=29876&rft_id=info:doi/10.1021%2Facsomega.2c02766&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2470-1343&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2470-1343&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2470-1343&client=summon |